<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650271</url>
  </required_header>
  <id_info>
    <org_study_id>AEVT-HCC</org_study_id>
    <nct_id>NCT02650271</nct_id>
  </id_info>
  <brief_title>Adjuvant Entecavir for Postoperative HBV-HCC</brief_title>
  <official_title>Adjuvant Entecavir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the effect of antiviral therapy with entecavir and lamivudine for
      hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included
      patients will randomly divide into two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is associated with a poor prognosis, and its incidence has
      increased dramatically in many countries. Hepatectomy is a radical therapy for early-stage
      HCC. However, even after radical resection, the prognosis for HCC patients remains
      discouraging because of the high recurrence rate and frequent incidence of intrahepatic
      metastasis. Therefore, preventing HCC recurrence is very important.

      Hepatitis B virus (HBV) infection is the major risk factor for HCC development in China. Some
      retrospective studies have shown that lamivudine or entecavir treatment for HBV-related HCC
      patients can effectively reduce the HCC recurrence rate and increase the survival rate after
      hepatectomy. However, which drug has more efficacy has not been addressed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Perioperative reactivation of hepatitis B virus replication</measure>
    <time_frame>1-month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be received entecavir (10 mg/d) after 3 days of liver resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Patients will be received entecavir (10 mg/d) after 3 days of liver resection.</description>
    <arm_group_label>Entecavir</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.</description>
    <arm_group_label>Lamivudine</arm_group_label>
    <other_name>LAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Underwent open hepatic resection.

          -  Diagnosis of HCC was confirmed by histopathological examination of surgical samples in
             all patients.

          -  HBsAg (+).

          -  Child-Pugh A liver function.

        Exclusion Criteria:

        - Anti-HCV(+)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jian-Hong Zhong, MD</last_name>
    <phone>86-771-5330855</phone>
    <email>zhongjianhong66@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Hong Zhong, MD</last_name>
      <email>zhongjianhong66@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013 Sep;10(3):158-64. doi: 10.7497/j.issn.2095-3941.2013.03.006.</citation>
    <PMID>24379991</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>adjuvant</keyword>
  <keyword>entecavir</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>hepatic resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

